Editas Medicine, Inc. (NASDAQ:EDIT) Shares Acquired by Trexquant Investment LP

Trexquant Investment LP lifted its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT) by 28.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 241,754 shares of the company’s stock after buying an additional 54,245 shares during the period. Trexquant Investment LP owned approximately 0.30% of Editas Medicine worth $2,449,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in EDIT. Dimensional Fund Advisors LP lifted its stake in shares of Editas Medicine by 40.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,392,396 shares of the company’s stock worth $24,236,000 after buying an additional 690,366 shares during the period. Vanguard Group Inc. raised its holdings in shares of Editas Medicine by 4.5% during the third quarter. Vanguard Group Inc. now owns 8,536,208 shares of the company’s stock worth $66,582,000 after purchasing an additional 370,734 shares during the last quarter. International Assets Investment Management LLC raised its holdings in shares of Editas Medicine by 1,183.6% during the fourth quarter. International Assets Investment Management LLC now owns 288,269 shares of the company’s stock worth $28,457,000 after purchasing an additional 265,812 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Editas Medicine by 32.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 688,964 shares of the company’s stock worth $5,374,000 after purchasing an additional 170,694 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Editas Medicine during the third quarter worth $944,000. 71.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on EDIT shares. Barclays reduced their target price on shares of Editas Medicine from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Thursday, May 9th. JPMorgan Chase & Co. raised their target price on shares of Editas Medicine from $8.00 to $9.00 and gave the stock a “neutral” rating in a report on Tuesday, February 27th. Citigroup reduced their target price on shares of Editas Medicine from $16.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Morgan Stanley raised shares of Editas Medicine from an “underweight” rating to an “equal weight” rating and set a $7.00 target price for the company in a report on Thursday, May 9th. Finally, StockNews.com cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a report on Thursday, May 9th. One analyst has rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Editas Medicine has a consensus rating of “Hold” and an average price target of $13.90.

Insider Transactions at Editas Medicine

In related news, Director Jessica Hopfield bought 45,000 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was acquired at an average price of $5.64 per share, with a total value of $253,800.00. Following the completion of the purchase, the director now directly owns 67,700 shares of the company’s stock, valued at $381,828. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Jessica Hopfield bought 45,000 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was acquired at an average price of $5.64 per share, with a total value of $253,800.00. Following the completion of the purchase, the director now directly owns 67,700 shares of the company’s stock, valued at $381,828. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Baisong Mei sold 20,327 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $9.42, for a total transaction of $191,480.34. Following the sale, the senior vice president now directly owns 141,543 shares of the company’s stock, valued at approximately $1,333,335.06. The disclosure for this sale can be found here. Corporate insiders own 1.90% of the company’s stock.

Editas Medicine Stock Down 3.4 %

EDIT opened at $5.63 on Friday. Editas Medicine, Inc. has a fifty-two week low of $4.91 and a fifty-two week high of $11.91. The company has a fifty day moving average of $6.22 and a two-hundred day moving average of $8.13.

Editas Medicine (NASDAQ:EDIT) last released its earnings results on Wednesday, May 8th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.13). The company had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $11.14 million. Editas Medicine had a negative return on equity of 47.34% and a negative net margin of 239.36%. The firm’s revenue for the quarter was down 88.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.71) EPS. Sell-side analysts predict that Editas Medicine, Inc. will post -2.67 earnings per share for the current fiscal year.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.